30 C
Vientiane
Saturday, May 10, 2025
spot_img
Home Blog Page 509

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

  • Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience
  • Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI
  • Company to advance innovative multi-payload programs designed to maximize therapeutic benefit for cancer patients by overcoming limitations of existing single-payload therapies

SEATTLE and SINGAPORE, March 3, 2025 /PRNewswire/ — Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187.0 million Series A financing round. This financing was led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors, including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The newly formed company, with headquarters in Seattle and Singapore, intends to use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program.

In conjunction with the financing, Callio Therapeutics has entered into an exclusive worldwide license agreement with Hummingbird Bioscience for its multi-payload ADC platform in oncology, and associated intellectual property and pipeline assets, in exchange for equity, potential milestone payments and royalties.

“We are delighted to be launching Callio Therapeutics with the support of Frazier Life Sciences and this syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy,” said Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics. “This new generation of ADC therapies may meaningfully improve outcomes for patients.”  

Leadership Team

The founding Callio Therapeutics management team comprises individuals with extensive experience from leading biotechnology and biopharmaceutical companies including ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, Hummingbird Bioscience and Genentech:

  • Piers Ingram, PhD, Chief Executive Officer
  • Jerome Boyd-Kirkup, PhD, Chief Scientific Officer
  • Naomi Hunder, MD, Chief Medical Officer
  • Angèle Maki, PhD, Chief Business Officer

“The multi-payload ADCs being developed at Callio Therapeutics have the potential to address large unmet medical needs by overcoming many of the limitations of existing ADCs,” said Adam Simpson, Executive Board Chair of Callio Therapeutics and Venture Partner at Frazier Life Sciences. “With the expertise of the Callio Therapeutics team, together with access to the innovative multi-payload ADC technology, we believe that Callio Therapeutics will be the first company to show the clinical benefit of this exciting new multi-payload ADC approach and is well positioned to transform cancer therapy.”

About Callio Therapeutics
Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics’ lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information, please visit www.calliotx.com and follow Callio Therapeutics on LinkedIn.

About Frazier Life Sciences
Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier Life Sciences, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York and London. For more information about Frazier Life Sciences, please visit frazierls.com and follow on LinkedIn.

About Hummingbird Bioscience
Hummingbird Bioscience is a Singapore-based biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience’s computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity.  At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedInX (formerly Twitter), and YouTube.

KPM Analytics Secures Legal Victory in Trade Secret Misappropriation Case

Court awards $10M to KPM Analytics in Trade Secret Theft and Tortious Interference Case, Reinforcing Commitment to Innovation and Fair Competition.

WESTBOROUGH, Mass., March 3, 2025 /PRNewswire/ — KPM Analytics, a global leader in analytical instrumentation for food and agriculture industries, has been awarded damages, attorney fees, and interest, totaling just over $10 million in a decisive legal victory against Blue Sun Scientific, LLC, the Innovative Technologies Group & Co., Ltd., and certain ex-KPM employees. In addition to the awarded monetary damages, the United States District Court for the District of Massachusetts also granted KPM Analytics’ requests for a permanent injunction against the defendants, including Blue Sun Scientific, LLC, prohibiting the defendants from offering to sell certain NIR products, services, hardware, software, or data to customers.

The 11-day trial of KPM Analytics North America Corporation vs. Blue Sun Scientific, LLC, The Innovative Technologies Group & Co., Ltd., Arnold Eilert, Robert Gajewski, Rachael Glenister, and Irvin Lucas (Civil Action No. 21-CV-10572-MRG), which concluded with a unanimous verdict on 6 counts of the Complaint against the defendants on May 17, 2023, stemmed from allegations that the defendants willfully and maliciously misappropriated confidential information and trade secrets concerning KPM Analytics near infrared (NIR) technologies. As a result, the court awarded exemplary damages, doubling the compensatory damages against certain defendants. 

“This verdict is not just a win for KPM Analytics but for the entire industry,” said Brian Mitchell, Chief Executive Officer for KPM Analytics. “Innovation is the backbone of our business, and we will always take the necessary steps to protect our proprietary technology from unlawful use.”

KPM would like to extend its gratitude to the dedicated legal team, Sunstein LLP and Morse Barnes-Brown & Pendleton, PC, expert witnesses, and all those involved in the two-year long case, whose unwavering support and diligent efforts were instrumental in achieving this significant victory. The verdict serves as a reminder that KPM will not tolerate the misappropriation of its trade secrets and will take all necessary legal measures to safeguard its valuable intellectual property.

About KPM Analytics

KPM Analytics is a global leader in scientific instrumentation and vision process machinery, focused primarily on analyzing critical parameters within the food, feed, agriculture, and environmental sectors. We provide a comprehensive range of products and services to uniquely solve our customers’ problems. Our brands include AMS Alliance, Bruins Instruments, CHOPIN Technologies, EyePro System, Process Sensors, Sensortech, Sightline, Smart Vision Works, and Unity Scientific. Each has a long history of delivering advanced and reliable analysis solutions to ensure product quality and optimize process efficiency, with customer service at the center of everything we do. Visit www.kpmanalytics.com to learn more.

Media contacts:

Andy Dambeck

Marketing Manager

adambeck@kpmanalytics.com

774-399-0477

 

Frost & Sullivan Recognizes Cynerio for Advancing Healthcare Cybersecurity with Its NDR-H Solution to Combat Cyber Threats

Cynerio’s NDR-H Solution enables deep packet inspection, comprehensive network traffic analysis with real-time threat detection and response, and proactive auto identification and analysis of connected devices.

SAN ANTONIO, March 3, 2025 /PRNewswire/ — Frost & Sullivan recently analyzed the healthcare security industry and, based on its assessment, recognizes Cynerio with the 2025 North American Enabling Technology Leadership Award. Realizing just how extensive healthcare cybersecurity challenges are for organizations beginning to build out their security programs, the company offers customers a single platform composed of three core offerings to meet the most prevalent organizational needs. Cynerio has devoted critical investment and development time to the deep packet inspection capabilities of its technical appliance. These efforts have been key to developing its Healthcare Cybersecurity Platform over the past six years. Cynerio’s Network Detection and Response for Healthcare (NDR-H) solution provides comprehensive network traffic analysis with real-time threat detection and response capabilities against the most common attack vectors. These include ransomware, malware, and common breach patterns that have been observed or reported by other healthcare entities as part of threat intelligence and collaboration initiatives.

Cynerio’s Medical Device Security solution offers proactive automatic identification and analysis of the connected devices present in the organization’s network to determine the optimal utilization and security of these assets. The solution also includes mitigation recommendations or best practices that can be enacted, such as micro-segmentation guidance, patch recommendations, or new use cases, to improve an asset’s overall efficiency. In doing so, the solution offers both security and organizational guidance. The company’s Complete Asset Visibility solution provides a single pane of glass view of all the connected technologies within the organization, including IT, operational technologies (OT), IoT, and Internet of Medical Things (IoMT) assets.

Danielle VanZandt, research manager for security at Frost & Sullivan, observed, “Cynerio’s multi-faceted platform aligns well with the triage-centric operational methodology that is fundamental to the healthcare industry, enabling security teams to efficiently determine the most prescient mitigation actions and better prioritize security objectives without overwhelming personnel.”

Cynerio’s Healthcare Cybersecurity Platform enables healthcare security teams to gain the visibility they require, determine the current security posture of their connected assets, and enact mitigation measures for improvement while having real-time awareness of the threats targeting them. The NDR-H solution meets industry demands and combats the rising wave of cyberattacks, actively tackling customers’ most pressing security challenges. Cynerio can also accelerate its internal product evolution based on these discussions, identify any new threats or attack vectors as they appear, and deploy an updated platform to customers to defend against the latest threats. Customers trust Cynerio as a knowledgeable and reliable partner that can support the deployment of their healthcare cybersecurity programs and keep them informed on the latest developments through continuous feedback.

“Cynerio has emerged as a key partner for healthcare customers looking to gain visibility into their entire organizational infrastructure, secure an expansive network of connected devices, and actively detect and combat cybersecurity threats as the healthcare sector continues to build out its security standards and best practices. Through the company’s robust Healthcare Cybersecurity Platform, Cynerio offers customers a centralized platform that addresses cybersecurity challenges across the organization, appealing to multiple stakeholders and connecting customers with Cynerio’s subject matter experts who serve as guides through this ever-changing industry,” added Danielle. With its robust cybersecurity platform and robust knowledge of the healthcare cybersecurity ecosystem performance, Cynerio earns Frost & Sullivan’s 2025 North American Enabling Technology Leadership Recognition in the healthcare security industry.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products, but also enables the development of new products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

Access the full Frost & Sullivan 2025 North American Enabling Technology Leadership Report here.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Camila Tinajero
P: +54911 6713 2748
E:Camila.Tinajero@frost.com

About Cynerio    

Cynerio empowers healthcare organizations with a comprehensive cybersecurity platform designed to protect medical environments from evolving cyber threats. With real-time threat detection, automated risk mitigation, and strategic micro-segmentation guidance, Cynerio helps hospitals and healthcare providers secure their networks, protect patient data, and ensure the resilience of connected devices. By delivering NDR-H, Medical Device Security, and Complete Asset Visibility, Cynerio provides healthcare security teams with the tools they need to prevent cyberattacks, maintain compliance, and enhance patient safety.

For more information, visit www.cynerio.com

CBAK Energy to Participate at Upcoming Jefferies 6th Asia Forum in Hong Kong

DALIAN, China, March 3, 2025 /PRNewswire/ — CBAK Energy Technology, Inc. (NASDAQ: CBAT) (“CBAK Energy”, or the “Company”), a leading lithium-ion battery manufacturer and electric energy solution provider, today announced its participation in the following investor conference – Jefferies 6th Asia Forum (“Jefferies Forum” or the “Conference”) in Hong Kong.

On Tuesday, March 18, 2025 at 4:00 PM Beijing/Hong Kong Time (3:00 AM U.S. Eastern Time on Tuesday, March 18, 2025), CBAK Energy management will host a group meeting at the Jefferies Forum. The Company will provide a comprehensive overview of corporate strategy and industry outlook, and will engage in a Q&A session at the end. For investors who wish to speak with the management, please contact the even team of Jefferies at Jefferies_Asia_Events@jefferies.com or the IR team of CBAK Energy at ir@cbak.com.cn.

About CBAK Energy

CBAK Energy Technology, Inc. (NASDAQ: CBAT) is a leading high-tech enterprise in China engaged in the development, manufacturing, and sales of new energy high power lithium batteries. The applications of the Company’s products and solutions include electric vehicles, light electric vehicles, electric tools, energy storage, uninterruptible power supply (UPS), and other high-power applications. In January 2006, CBAK Energy became the first lithium battery manufacturer in China listed on the Nasdaq Stock Market. CBAK Energy has multiple operating subsidiaries in Dalian and Nanjing, as well as a large-scale R&D and production base in Dalian.

For more information, please visit www.ir.cbak.com.cn.

Safe Harbor Statement

This press release contains forward-looking statements, which are subject to change. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All “forward-looking statements” relating to the business of CBAK Energy Technology, Inc. and its subsidiary companies, which can be identified by the use of forward-looking terminology such as “believes”, “expects” or similar expressions, involve known and unknown risks and uncertainties which could cause actual results to differ materially. These factors include but are not limited to: the ability of the Company to meet its contract or agreement obligations; the uncertain market for the Company’s lithium battery cells; business, macroeconomic, technological, regulatory, or other factors affecting the profitability of battery cells designed for energy storage; and risks related to CBAK Energy’s business and risks related to operating in China. Please refer to CBAK Energy’s most recent Annual Report on Form 10-K, as well as other SEC reports that have been filed since the date of such annual report, for specific details on risk factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. CBAK Energy’s actual results could differ materially from those contained in the forward-looking statements. CBAK Energy undertakes no obligation to revise or update its forward-looking statements in order to reflect events or circumstances that may arise after the date of this release unless expressly requested by applicable law.

For investor and media inquiries, please contact:

In China:

CBAK Energy Technology, Inc.
Investor Relations Department
Email: ir@cbak.com.cn

 

Moldova e-Governance Agency Joins EU Digital Identity Wallet Pilot

CHIȘINĂU, Moldova, March 3, 2025 /PRNewswire/ — The e-Governance Agency of Moldova (AGE) is proud to announce its participation in the second round of Large-Scale Pilot Projects (LSP) for the EU Digital Identity Wallet (EUDI). As a member of the WE BUILD consortium, selected by the European Commission, AGE strengthens Moldova’s role as a forward-thinking digital nation committed to aligning with EU standards.

Moldova e-Governance Agency Joins EU Digital Identity Wallet Pilot
Moldova e-Governance Agency Joins EU Digital Identity Wallet Pilot

This initiative underscores Moldova’s dedication to digital transformation, driven by its rapidly expanding IT sector. The Moldova Innovation Technology Park exemplifies this growth, housing over 2,100 companies from over 40 countries and contributing 5% to the national GDP. Its operational model and competitive 7% flat tax on revenue have attracted top-tier tech firms, reinforcing Moldova’s position as regional digital hub.

AGE will be instrumental in developing and testing secure Business-to-Government solutions to integrate digital wallets with public services across the EU. The initiative fosters best practice exchanges and supports the widespread adoption of digital identity wallets for both public and private e-services.

Moldova is already leading in this domain with a preliminary version of a Digital Identity Wallet embedded in the “Documents” module of EVO, the national public services app. Additionally, EVOSign, a robust authentication tool currently in pilot testing, showcases Moldova’s commitment to advancing EUDI, with plans to expand into a full-fledged electronic signature application.

This marks Moldova’s first project as a beneficiary of the Digital Europe Programme, reaffirming its commitment to digital innovation and EU alignment. EUDI wallets will offer individuals and businesses secure means to access online services, store and share digital documents, and create legally binding electronic signatures. Each EU Member State will develop its own wallet application based on common specifications, ensuring interoperability.

The LSPs are crucial for refining EUDI development, testing specifications, and shaping the Implementing Acts that will formally integrate EUDI into EU law. These projects, funded by the Digital Europe’s €7 billion budget, aim to drive digital adoption across sectors. The WE BUILD consortium, with approximately 200 partners from EU Member States and the private sector, will lead this initiative. The project will launch in autumn 2025 and will run for 24 months, guided by Dutch and Swedish governmental bodies.

Moldova formalized its association with the Digital Europe Programme in February 2024, AGE serving as the national contact point, ensuring continued progress in the country’s digital transformation.

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR MARCH 3RD

NEW YORK, March 3, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. The NYSE façade was illuminated over the weekend to raise awareness of Rare Disease Day, which took place on Friday, February 28th.

 

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR MARCH 3RD

Trinity Chavez delivers the pre-market update on March 3rd

  • Investors look ahead to Fed Chair Jerome Powell’s comments on Friday
  • Anticipating a week of key economic reports, including jobless claims
  • Markets aim for a strong response after last week’s mixed performance

Watch NYSE TV Live every weekday 9:00-10:00am ET 

 

Bruno Marc Redefines Men’s Oxford Shoes for Spring 2025

Distinct Designs for Every Defining Moment — From Office to Weekend

NEW YORK, March 3, 2025 /PRNewswire/ — The Bruno Marc Spring 2025 Men’s Oxford Collection redefines what it means to wear an Oxford. Designed for men who demand sophistication without sacrifice, this collection seamlessly blends classic craftsmanship with cutting-edge comfort, delivering lightweight flexibility, effortless polish, and all-day ease. Whether stepping into the boardroom, out on the town, or anywhere in between, this collection empowers men to move with confidence. 

Bruno Marc redefines classic dress shoes with its Oxford Collection, seamlessly blending timeless sophistication with premium sneaker-like comfort. This innovative lineup ushers in a new era of performance-driven elegance.
Bruno Marc redefines classic dress shoes with its Oxford Collection, seamlessly blending timeless sophistication with premium sneaker-like comfort. This innovative lineup ushers in a new era of performance-driven elegance.

With an unwavering commitment to redefining modern luxury, Bruno Marc has engineered a collection that challenges the limitations of traditional dress shoes. By fusing timeless Oxford sophistication with premium sneaker comfort, the Oxford Collection brings a new era of performance-driven elegance—because the right shoes don’t just complement an outfit; they set the tone for success.

Spring Forward in Revolutionized Oxfords for Every Moment 

BUSINESS CASUAL: The Competitive Edge in Style 

For professionals who demand sharp style with all-day comfort, this selection delivers an effortless transition from work to after-hours. Whether dominating meetings, leading presentations, or networking over dinner, these Oxfords redefine business casual with a performance-driven edge.

  • CrossFlex GentEdge – A refined yet relaxed Oxford with a premium vegan leather upper, arch-supporting cushioning, and a flexible sole for power moves with ease.
  • MaxFlex SuiteCraft – Designed for next-level comfort, this breathable wingtip Oxford features moisture-wicking lining, shock-absorbing support, and a lightweight, modernized design.
  • KnitFlex SmartCraft – A tech-driven Oxford with a stretch-knit upper, cushioned midsole, and grippy outsole for superior traction and step-by-step comfort.

ACTIVE: Laid-back, never off your game. 

For the man who moves through life with ease, this lineup blends refined style with luxurious, sneaker-like comfort. Whether grabbing coffee, navigating city streets, or meeting friends for brunch, these versatile designs deliver effortless sophistication with every step.

  • MaxFlex ActiveMetro – A hybrid Oxford-sneaker with a breathable knit upper, responsive cushioning, and slip-resistant traction — all the polish, none of the stiffness.
  • Theo sneakers – A certified slip-resistant work shoe with a shock-absorbing EVA midsole, designed for all-day wear in work settings without compromising style.
  • Sage Slip-On Loafers – A modern, easygoing loafer with a lightweight sole, stretch-knit upper, and cloud-like comfort for all-day ease.

DRESS: Big Stage, Big Style.

These styles are built for life’s defining moments—whether it’s a wedding, anniversary, graduation ceremony, or milestone celebration. Designed for the modern gentleman, these Oxfords combine timeless aesthetics with next-generation comfort and flexibility.

  • MaxFlex SuiteCraft – A statement wingtip Oxford that merges classic detailing with modern performance technology for style that rises to every occasion.
  • CrossFlex NeatPolish+ – A sleek and structured dress shoe with a genuine vegan leather upper, advanced arch support, and a shock-absorbing footbed for effortless sophistication.
  • Everett Classic Velvet Loafers – A show-stopping slip-on featuring a patent vegan leather upper, luxe velvet detailing, and a TPR outsole for a polished, elevated finish.

Designed for the Modern Man: Lightweight. Flexible. Unstoppable.

Traditional dress shoes often come with a trade-off between style and comfort—but not anymore. The Bruno Marc Spring 2025 Oxford Collection is made with premium materials, performance-inspired outsoles, and innovative cushioning, ensuring that every step is as smooth as it is stylish. With ergonomic footbeds, breathable linings, and lightweight flexibility, these Oxfords are made for the man who refuses to be slowed down—whether he’s stepping into the office, onto the streets, or onto life’s biggest stages.

Step Into the New Era of Oxfords

Spring style calls for versatility, comfort, and effortless polish—and the Bruno Marc Spring 2025 Oxford Collection delivers. From high-stakes boardrooms to casual rooftop gatherings, these five styles ensure you’re always stepping forward in confidence.

Available Now

Explore the Bruno Marc Oxford collection on Amazon, Official Website, TikTok, JustFab, and in selected retail stores. Step into this season’s most coveted styles and elevate your wardrobe with our exceptional range of Oxfords. Discover unparalleled value and quality, where timeless design meets enduring comfort.

About Bruno Marc

Bruno Marc is on a mission to redefine modern luxury, offering impeccably crafted footwear that embodies sophistication without the premium price. With an unwavering commitment to quality and refinement, Bruno Marc delivers shoes that blend timeless elegance with contemporary style, making high-end fashion accessible to every man. By prioritizing craftsmanship and attention to detail, Bruno Marc ensures that luxury is not just a statement but a standard, bringing a touch of sophistication to everyday life.

Tantech Holdings Regains Compliance with NASDAQ Minimum Bid Price Requirement

LISHUI, China, March 3, 2025 /PRNewswire/ — Tantech Holdings Ltd (NASDAQ: TANH) (“Tantech” or the “Company”) announced today that on February 28, 2025, it received notification from The Nasdaq Stock Market LLC (“NASDAQ”) confirming the Company has regained compliance with NASDAQ’s minimum bid price requirement under Listing Rule 5550(a)(2). NASDAQ noted this matter is now closed.

About Tantech Holdings Ltd

For the past decade, Tantech has been a highly specialized high-tech enterprise producing, researching and developing bamboo charcoal-based products with an established domestic and international sales and distribution network. Since 2017, when the Company acquired 70% of Shangchi Automobile, a vehicle manufacturer based in Zhangjiagang City, Jiangsu Province, it has manufactured and sold vehicles. The Company established two new subsidiaries, Lishui Smart New Energy Automobile Co., Ltd. and Zhejiang Shangchi New Energy Automobile Co., Ltd., in November 2020, to produce and sell street sweepers and other electric vehicles. The Company is fully ISO 90000 and ISO 14000 certified and has received a number of national, provincial and local honors, awards and certifications for its products and scientific research efforts. The Company’s subsidiary, First International Commercial Factoring (Shenzhen) Co., LTD, is engaged in commercial factoring for businesses in and related to its supply chain. For more information please visit: https://tanhtech.com/.

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning the sales, plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Tantech Holdings Ltd
Investor Relations
Tel: +86 (578) 226-2305
ir@tantech.cn